In Tucson, an FDA nomination shortages the map

WASHINGTON — Health policy in this town is a budget fight wearing a lab coat. On July 7, 2026, an FDA nomination walked into the argument and refused to leave. The scene at the Ambassador Bridge approaches was the kind of Washington tableau that looks choreographed until you watch the aides check their phones. In Tucson, an FDA nomination shortages the map is the polite way to describe a capital that is fighting a war, an election and a trade rupture at the same time.

The nut of it is simple, and Canadians should not dress it up. American power still sets the tempo for North America, but it is being spent with less patience and more theatre. An FDA nomination is where that impatience showed on July 7, 2026. The war with Iran was 118 days old, which in Washington is long enough for the first briefings to go stale and not long enough for anyone to describe an off-ramp with a straight face. Shipping through Hormuz had become a daily wager. A barrel of crude around US$98.9 did more to set the president’s mood than any prepared remark.

There is always a paper trail. Staffers circulated a farm-state biofuels carve-out with the serial number H.R. 3318, which is how Washington pretends a political choice is a technical one. In Judiciary, members asked questions they already knew the answers to, then left to tape hits that would be clipped before dinner. The public argument was about principle. The private argument was about 49 per cent of a slice of the map that still decides who runs the House.

"An FDA nomination is not a messaging problem. It is a governing problem," a refining executive who asked not to be named told Maclean’s. The conversation happened the way they happen now: off to the side, on background, with a glance at the door. "You can survive a bad clip. You cannot survive a month of prices that people feel in the driveway." In Tucson, that sentence would not be a metaphor.

American drug prices are a Canadian tourist industry. They are also a domestic uprising every time a new class of medicine — the GLP-1s most obviously — meets an insurer’s spreadsheet. Nominations at FDA and HHS have become loyalty tests. Public health, after the last decade, is a culture war with a mortality table attached.

The data does not care about the talking points. Payrolls have been moving in fits — the last print Washington could agree on put job growth near 36,000 — while gasoline and diesel have done the political damage. A crude marker near US$98.9 is the number that follows the president from the briefing room to the tarmac. Polling shared on the Hill, always with a caveat and a brand name, has the president in the neighbourhood of 42 per cent on the economy, which is not a number a party wants to take into a midterm if it can help it.

For Canada, this is not a spectator sport. New Brunswick’s energy corridor feels American decisions in a week, not a quarter. Prime Minister Mark Carney’s government has spent 2026 learning that friendship is not a trade policy. Officials in Ottawa still use the old words — ally, partner, integrated — while building a second set of plans in case the first set fails. A refining executive who asked not to be named put it more bluntly: “If you are waiting for Washington to remember you, you have already lost the week.”

The American health fight exports its shortages, its prices and its arguments. Canada’s waiting rooms already know this. The bureau’s job is to catch the policy before it arrives as a shortage.

What happens next is not a mystery so much as a calendar. The midterms sit on the other side of every meeting. A House that can flip by 10 seats concentrates the mind. Committees will keep holding hearings — Judiciary is already teeing up another round — and the White House will keep trying to define the story before the story defines the election. Canada will keep a desk in the room and a notebook on what the room pretends not to see.

By nightfall the motorcade lights had done their usual work on Pennsylvania Avenue and the city had returned to its other job, which is pretending that the next cycle is still far away. It is not. November is close enough to taste. The Maclean’s Washington Bureau will keep the lights on in a rented corridor of this capital because the decisions taken here do not stay here. They show up in Canadian paycheques, Canadian ports and Canadian cabinet notes. That is the job.